> ## Documentation Index
> Fetch the complete documentation index at: https://au-2a4a5dc8.mintlify.site/llms.txt
> Use this file to discover all available pages before exploring further.

# Unseen

> Find the prescribers nobody calls on, from public data alone.

Unseen answers questions like "Georgia dermatologists who prescribe dupilumab and take almost no industry money". It joins four public datasets on the National Provider Identifier (NPI) and returns a ranked list.

```sh theme={null}
openlabel unseen "Endocrinologists in Mississippi prescribing GLP-1s with under $1,000 in industry payments"
openlabel unseen --state MS --specialty Endocrinology --drug Semaglutide --drug Tirzepatide --max-payments 1000
```

```text theme={null}
Endocrinology in MS prescribing Semaglutide, Tirzepatide, at most $1,000 in industry payments 2023–2025

  NPI          Name                                  Location            Claims 2024   Payments 2023–2025   Possible trials
  1417339268   Aboorva Kambiliampatti Sudhakar, MD   Hattiesburg, MS             431                 $390   none
  1871694646   Daniel Mccall, MD                     Hattiesburg, MS             284                 $588   none
  ...
  5 shown from 35 top prescribers checked.
```

## How it works

**1. Prescribers**

Medicare Part D prescribing (2024) for the drugs, filtered to the state and specialty. A drug's brand forms, such as Dupixent Pen and Dupixent Syringe, are summed per prescriber, then prescribers are ranked by claims.

**2. Industry payments**

Open Payments general payments for 2023, 2024 and 2025, per prescriber. Unseen walks down the ranking in batches and stops once it has enough prescribers under the payment limit.

**3. Practice location**

The NPPES registry supplies the practice address and credential.

**4. Possible trial sites**

ClinicalTrials.gov sites in the prescriber's state that carry their name, as the site name or a site contact, in studies that started in 2021 or later.

## Questions or flags

A question is turned into a search by Claude. Part D records drugs, not diagnoses, so "psoriasis prescribing" becomes the drugs that treat psoriasis. "No industry contact" becomes a payment limit of $0, and "low contact" $100 unless you give a number.

Flags skip the model. `--state`, `--specialty` and at least one `--drug` are required together; `--max-payments` and `--limit` are optional. A flag also overrides what a question set, so `--max-payments 500` with a question keeps the question's drugs and changes only the limit.

## What the data can't tell you

> [!WARNING]
>
> Read the output as leads, not facts.

* Part D 2024 is the newest year CMS has published, so prescribing runs about two years behind.
* Part D covers drugs dispensed at pharmacies. Infused drugs billed under Part B, such as most oncology infusions, never appear, and Unseen lists any drug it found no rows for.
* Part D only covers Medicare patients. A prescriber with a younger patient population will rank lower than their real volume.
* ClinicalTrials.gov has no NPIs. A trial match means the name appears on a site in the prescriber's state, and needs checking.
* Manufacturers do not have to report payments below a small yearly threshold, so \$0 means "nothing reported", not "no contact".


This documentation is built and hosted on [Mintlify](https://mintlify.com), a developer documentation platform.